What is InnFocus?
InnFocus, Inc. was a medical device company focused on developing novel solutions for unmet needs in ocular care, particularly in the treatment of glaucoma. The company's core innovation was its proprietary SIBS (Segmented Ingrowth Bio-compatible Scaffold) polymer technology, designed for use in surgical implants. This advanced biomaterial aimed to improve patient outcomes by providing a stable and effective platform for glaucoma drainage implants. InnFocus's strategic focus on developing cutting-edge ophthalmology products placed it at the forefront of medical technology innovation in eye care.
How much funding has InnFocus raised?
InnFocus has raised a total of $62.9M across 4 funding rounds:
Series A
$2M
Series B
$13.5M
Unspecified
$13.5M
Series C
$33.9M
Series A (2011): $2M, investors not publicly disclosed
Series B (2013): $13.5M led by Undisclosed
Unspecified (2013): $13.5M supported by Undisclosed
Series C (2015): $33.9M featuring Santen Pharmaceutical Co., Ltd and HOYA
Key Investors in InnFocus
Santen Pharmaceutical Co., Ltd
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company with a strong specialization in ophthalmology, holding a leading position in the Japanese market and significant global presence. Their investment in InnFocus likely aimed to bolster their pipeline of innovative glaucoma treatment devices.
HOYA
HOYA is a Japanese multinational company specializing in high-tech products and medical devices, including a significant presence in vision care and healthcare. Their participation suggests a strategic interest in advancing ocular health technologies.
Undisclosed Investors
What's next for InnFocus?
Following its acquisition by Santen Pharmaceutical Co., Ltd. in 2016, InnFocus's technology and product pipeline have been integrated into Santen's broader ophthalmology portfolio. The substantial capital raised throughout its funding history, culminating in a major Series C round, enabled InnFocus to advance its research and development efforts and prepare for commercialization. The strategic investment from Santen Pharmaceutical signifies a new phase of growth and market expansion, leveraging Santen's global reach and expertise in the ophthalmic pharmaceutical market to bring InnFocus's innovations to a wider patient base.
See full InnFocus company page
